[[1]](#footnote-2)



**May 08, 2025**

**Reinsurance Coverage of Three Additional High-Cost Specialty Drugs (BIO)**

AHCCCS is pleased to announce the addition of the following drug to the High-Cost Specialty Drug Reinsurance Program effective beginning October 1, 2024:

**Duvyzat** (Givinostat) is an FDA approved medication used for the treatment of Duchenne muscular dystrophy (DMD) in people 6 years of age or older.

The following drugs are effective beginning October 1, 2025:

**Tecelra** (afamitresgene autoleucel) is an FDA approved genetically modified autologous T Cell immunotherapy used for the treatment of synovial sarcoma.

**Tepezza** (teprotumumab-trbw) is an FDA approved medication used to treat thyroid eye disease (TED).

The Request Letter for Catastrophic Reinsurance, on the AHCCCS website, will be updated with the new high-cost specialty drugs in the next few days. If your plan has a member that received Duvyzat on or after the effective date of October 1, 2024, you may submit a reinsurance request to AHCCCS Medical Management. The request must be received by AHCCCS Medical Management prior to June 30, 2025.

1. [↑](#footnote-ref-2)